✦ LIBER ✦

Targeted drug development in melanoma and nonsmall cell lung cancer: BRAF, MEK, and ALK inhibitors

✍ Scribed by Chi, Ming; Puzanov, Igor

Book ID: 118824736
Publisher: Springer-Verlag
Year: 2012
Tongue: English
Weight: 440 KB
Volume: 5
Category: Article
ISSN: 1865-5041
DOI: 10.1007/s12254-012-0058-4

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

ALK translocation and crizotinib in non-

ALK translocation and crizotinib in non-small cell lung cancer: An evolving paradigm in oncology drug development

✍ Giorgio Scagliotti; Rolf A. Stahel; Rafael Rosell; Nick Thatcher; Jean-Charles S 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 892 KB

Phase 1 and pharmacokinetic study of eve

Phase 1 and pharmacokinetic study of everolimus, a mammalian target of rapamycin inhibitor, in combination with docetaxel for recurrent/refractory nonsmall cell lung cancer

✍ Suresh S. Ramalingam; R. Donald Harvey; Nabil Saba; Taofeek K. Owonikoko; John K 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 151 KB 👁 2 views

[American Thoracic Society American Thor

[American Thoracic Society American Thoracic Society 2011 International Conference, May 13-18, 2011 • Denver Colorado - ()] C66. MOLECULAR TARGETS FOR THERAPEUTIC DEVELOPMENT IN LUNG CANCER - Resistant To Erlotinib, Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, Is Involved In Epithelial To Mesenchymal Transition, Cell Migration And Inflammation In A549, A Non-Small Cell Lung Cancer Cell Line

✍ Lee, Kyu Hwa; Lee, Sang Min; Yim, Jae Joon; Yoo, Chul Gyu; Kim, Young Whan; Han, 📂 Article 📅 2011 🏛 American Thoracic Society ⚖ 19 KB